Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMOFlipid versus Lipovenoes MCT in malnourished cirrhotic liver cancer patients undergoing hepatectomy
ChiCTR2100050001Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Jan 2021
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of SMOFlipid and Lipovenos in liver cancer, Cirrhosis and Malnutrition (2 arms), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoints: Change in leukotriene B5 from Day 1 to Day 6 and Change in interleukin-6 from Day 1 to Day 6. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
SMOFlipidLipovenos
03
Conditions
liver cancerCirrhosisMalnutrition
Beyond the preview
Go deeper on ChiCTR2100050001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050001.